What Is RhD? Its Role in Blood and Pregnancy

RhD is a protein found on the surface of red blood cells, and whether you carry it determines your “positive” or “negative” blood type label. When a blood bank stamps your card as O-positive or A-negative, the positive or negative part refers specifically to the D antigen in the Rh blood group system. Most people carry it and never think about it, but for the roughly 15 percent of people of European descent who lack it, RhD becomes medically significant during pregnancy and blood transfusions in ways that can be serious if overlooked.

The Protein on Your Red Blood Cells

The RhD protein is a 417-amino-acid molecule that sits in the membrane of your red blood cells, threading back and forth through the cell wall in what researchers describe as 13 membrane-spanning segments.¹ It does not float there alone. RhD forms a complex with several other membrane proteins, including a closely related protein called RhCE and a partner protein called RhAG. This entire Rh complex anchors into the cell’s internal skeleton and helps maintain the shape and flexibility of red blood cells.² In other words, Rh proteins are not just passive name tags. They play a structural role in keeping red blood cells working properly.

The RhD protein and the closely related RhCE protein differ by only 36 amino acid substitutions out of 417, a divergence of about 8 percent.¹ Despite that similarity, the immune system treats RhD as strikingly foreign when it encounters it on cells that don’t belong to the host. That immunological potency is what makes RhD matter in medicine.

How Someone Becomes RhD-Negative

If you are RhD-negative, you don’t carry a broken version of the protein. In most cases, the gene that codes for it is simply gone. The RHD gene sits on chromosome 1, flanked on both sides by similar DNA sequences called Rhesus boxes. During the formation of egg or sperm cells, those flanking sequences can misalign and cross over, causing the entire RHD gene to be deleted. This complete deletion is the most common reason people test as RhD-negative, especially in populations of European descent.³ In populations of African descent, the picture is more complicated. Some people carry an RHD pseudogene that is present but nonfunctional, while others carry hybrid genes that fuse parts of RHD and RHCE together, also resulting in no D protein on their cells.

Since you inherit one copy of the relevant chromosome from each parent, you need two nonfunctional or deleted copies to be RhD-negative. Carrying one working copy is enough to produce the protein on your red blood cells. That is why the trait runs in families but can seem to skip generations: two parents who are each carrying one deleted copy and one functional copy will both test as RhD-positive, but roughly a quarter of their children will inherit the deleted copy from both sides and test negative.

Who Is RhD-Negative Around the World

The frequency of RhD-negative status varies dramatically by ancestry. Among Basque populations in Europe, RhD-negative rates approach 30 to 35 percent, the highest anywhere. Across broader European-descent populations, it sits around 15 to 17 percent. In East Asian populations, it drops below 1 percent. Sub-Saharan African populations tend to fall somewhere in between, though the genetic mechanisms for being RhD-negative there differ from those common in Europe.

A large study of the Mexican population illustrates how these frequencies shift even within a single country. Researchers found that about 96 percent of the people studied were RhD-positive and about 4 percent RhD-negative, with regional variation tracking the degree of European versus Indigenous ancestry in different parts of the country.⁴

This geographic distribution has puzzled geneticists. If being RhD-negative puts pregnancies at risk, you would expect natural selection to push the deletion out of the gene pool. Yet it persists at high frequencies in Europe. Researchers using genomic data from multiple populations found no strong evidence that positive natural selection drove the RHD deletion to high frequency. Instead, the initial rise may have been a matter of chance: genetic drift or a founder effect in ancient European populations. Their simulations suggest that once the deletion reached an intermediate frequency, the selective pressure against it actually weakens, allowing it to be maintained by relatively modest random fluctuations.⁵ The evolutionary story, in other words, remains unfinished.

Why RhD Matters in Pregnancy

The medical significance of RhD comes down to a mismatch between a pregnant person and a fetus. If you are RhD-negative and your fetus is RhD-positive (having inherited the gene from the other parent), small amounts of fetal blood can cross the placenta and enter your circulation. Your immune system, having never seen the D antigen, may recognize those fetal red blood cells as foreign and produce antibodies against them. This process is called alloimmunization or sensitization.

Fetal-to-maternal bleeding is not limited to delivery. Research has shown that fetal red blood cells can be detected in the pregnant person’s blood well before procedures and throughout pregnancy, suggesting that low-level cell exchange between fetus and parent happens routinely from early in gestation.⁶ This means the immune system may get its first look at the D antigen months before birth.

The first pregnancy usually goes fine. The immune response takes time to build, and any antibodies produced may arrive too late and in too small a quantity to harm the first fetus. The problem is memory. Once your immune system has learned to recognize RhD, it responds faster and harder in any subsequent pregnancy with an RhD-positive fetus. Those antibodies cross the placenta, coat the fetal red blood cells, and trigger their destruction. The result is hemolytic disease of the fetus and newborn, which can range from mild anemia and jaundice to severe anemia, fluid buildup (hydrops fetalis), and fetal death if untreated.

How Doctors Monitor and Treat Alloimmunized Pregnancies

When an RhD-negative pregnant person already has anti-D antibodies, the clinical team needs a way to check whether the fetus is becoming anemic without resorting to invasive procedures. The standard tool is a Doppler ultrasound measurement of blood flow speed in the fetal middle cerebral artery. As a fetus becomes anemic, its blood becomes less viscous and flows faster. A peak velocity above a certain threshold strongly suggests significant anemia and the need for intervention.⁷ A prospective multicentre trial found this Doppler method to be highly sensitive for detecting anemia, sparing many fetuses from riskier procedures like amniocentesis or direct cord blood sampling.

When the Doppler readings indicate severe anemia, treatment involves intrauterine blood transfusion. A needle is guided through the pregnant person’s abdomen into the umbilical cord, fetal blood is sampled to confirm anemia, and compatible donor red blood cells are transfused directly into the fetal circulation at the same sitting.⁸ Some pregnancies require multiple transfusions over several weeks to keep the fetus stable until it is mature enough for delivery. The procedure carries risks, but it transformed outcomes for severely affected fetuses from near-certain death to survival rates well above 80 percent in experienced centers.

Preventing the Problem Before It Starts

The introduction of anti-D immunoglobulin (commonly known by brand names like RhoGAM) in the late 1960s and 1970s was one of the major successes in preventive medicine. Before prophylaxis programs existed, hemolytic disease of the newborn caused significant illness and death. The widespread use of anti-D injections drastically reduced these cases within a generation.

The concept is straightforward: if you give an RhD-negative person a dose of ready-made anti-D antibodies shortly after they have been exposed to RhD-positive fetal red blood cells, those antibodies clear the fetal cells from circulation before the immune system can mount its own response. Standard practice is to give one injection around 28 weeks of gestation and another within 72 hours of delivery if the newborn turns out to be RhD-positive. Additional doses are given after events that increase the risk of fetal-to-maternal bleeding, such as miscarriage, amniocentesis, abdominal trauma, or ectopic pregnancy.

How exactly the injected antibodies suppress the immune response is still debated. One hypothesis involves the rapid clearance of antibody-coated fetal red blood cells through specific immune receptors, with the degree of sugar modification on the antibody’s tail influencing how effectively it triggers that clearance.⁹ Ongoing research is working to replace the current product, which is derived from pooled human plasma, with a manufactured monoclonal antibody. A multicenter trial found that monoclonal anti-D was comparable to the traditional polyclonal preparation in preventing maternal sensitization.¹⁰ A synthetic source would remove the dependence on human donors and improve supply consistency.

Cell-Free DNA Testing Changes the Game

One of the more practical advances in recent years is the ability to determine a fetus’s RhD status from a simple blood draw from the pregnant person. Tiny fragments of fetal DNA circulate in the pregnant person’s blood, and a test can look for the RHD gene within those fragments. If you are RhD-negative and the test shows that your fetus is also RhD-negative, you can skip the anti-D injection entirely, since there is no mismatch to worry about. This avoids unnecessary use of a blood-derived product and saves limited supplies.

Two recent large U.S. studies put hard numbers on the accuracy of this approach. One evaluated 401 RhD-negative pregnant individuals and found 100 percent agreement between the cell-free DNA result and the newborn’s actual blood type, with no false negatives and no false positives.¹¹ A second, even larger validation study confirmed these results: all 356 RhD-positive fetuses were correctly identified, with a sensitivity of 100 percent and a specificity above 99 percent. The test even correctly identified fetuses carrying a nonfunctional RHD pseudogene, flagging them as truly RhD-negative despite having some RHD gene sequence present.¹² Several European countries already use this test routinely for all RhD-negative pregnancies. Adoption in the United States has been slower but is gaining momentum.

When a pregnant person is already sensitized, knowing the father’s genetic makeup can also help predict risk. If the father carries two copies of the functional RHD gene, every child will inherit one and be RhD-positive. If the father carries only one copy, each pregnancy has a roughly 50-50 chance of producing an RhD-negative fetus that is not at risk. Molecular tests to determine the father’s RHD gene dosage are used before entering into invasive fetal diagnostics.¹³

Weak D and Partial D Variants

Not everyone falls neatly into the RhD-positive or RhD-negative camp. Some people carry a version of the RHD gene that produces a protein with reduced amounts on the cell surface (weak D) or a protein that is missing some of the molecular features the immune system recognizes (partial D). Standard blood typing tests can give ambiguous results for these individuals.

The clinical dilemma is real. A person with a weak D type that produces enough protein to trigger an immune response in someone who is truly RhD-negative should donate blood as RhD-positive, to avoid sensitizing recipients. But a person with a partial D variant who is missing pieces of the D protein can themselves become sensitized if they receive RhD-positive blood, because their immune system treats the complete D protein as foreign.

Molecular testing has provided a practical way forward. The three most common weak D types in people of European descent (types 1, 2, and 3) are seldom if ever associated with producing anti-D antibodies, so individuals with these variants can safely be managed as RhD-positive for both transfusion and pregnancy.¹⁴ One particular partial D variant, called DVI, is the one most commonly associated with anti-D antibody production, and UK guidelines specifically recommend that patients be tested with reagents designed not to react with it, so these individuals are typed as RhD-negative and receive appropriate protection.¹⁵ This genotype-guided approach eliminates unnecessary anti-D injections for some pregnant individuals and conserves limited supplies of RhD-negative donor blood.

RhD in Transfusion Medicine

Outside of pregnancy, RhD status matters most during blood transfusions. The standard rule is simple: RhD-negative patients should receive RhD-negative blood, and RhD-positive patients can receive either. In emergency situations where the patient’s blood type is unknown, the historical protocol calls for type O-negative blood, the universal donor type.

But O-negative blood is in chronic short supply. It represents only about 7 percent of donations in populations of European descent and is far rarer in other populations. Some hospitals have adopted policies of giving O RhD-positive blood in emergencies to patients of unknown type, reserving O-negative exclusively for women of childbearing age. A prospective study of this approach found that the risk of patients developing anti-D antibodies afterward was low, in the range of 3 to 6 percent, while the policy saved more than 10 percent of total O RhD-negative blood demand.¹⁶ Hospital practices for women of childbearing potential remain inconsistent, with some institutions reserving O-negative blood for this group and others not, reflecting a tension between supply constraints and the consequences of sensitizing someone who may become pregnant.¹⁷

Rh-Null and the Structural Role of the Rh Complex

The rarest and most medically dramatic phenotype related to this system is Rh-null, sometimes called “golden blood.” Fewer than 50 individuals worldwide have been identified with this condition, in which not just RhD but the entire Rh complex is missing from the red blood cell membrane. These individuals lack all Rh antigens, meaning their blood can theoretically be donated to almost anyone with incompatibilities in the Rh system, making each known Rh-null person extraordinarily valuable to transfusion medicine.

But the absence of the Rh complex comes with consequences. Red blood cells need these proteins for structural integrity. Without them, the cells become misshapen, fragile, and prone to premature destruction. People with Rh-null syndrome show abnormalities in red blood cell shape, problems with how ions move across the membrane, and disrupted membrane composition.¹⁸ The resulting chronic low-grade hemolytic anemia ranges from barely noticeable to clinically significant. Laboratory research using cultured Rh-null red blood cells has confirmed that loss of the RhAG protein alone is enough to disrupt the entire complex, causing other membrane proteins to disappear from the cell surface as well.¹⁹

The Rh-null phenotype underscores a point that can get lost in the clinical focus on pregnancy and transfusion: the Rh proteins are not just antigens sitting on the cell surface waiting to cause immune trouble. They are integral structural and functional components of the red blood cell, and their complete absence damages the cell itself.

The Ancient History of the RH Genes

Humans are not the only primates with two types of RH genes. By studying a stretch of DNA within the RH gene across species, researchers showed that chimpanzees and gorillas also carry two versions of the gene, one resembling human RHD and the other resembling RHCE. The gene duplication that created both appears to have occurred in the common ancestor of humans, chimpanzees, and gorillas, making it at least several million years old. The two gene copies in that ancestor differed partly by a roughly 650-base-pair deletion that removed an inserted DNA element from one copy, a signature still visible in living species today.²⁰ The deep evolutionary conservation of the Rh complex across primates supports the idea that these proteins serve important functions in red blood cell biology well beyond their immunological side effects in human pregnancy.

RhD Status and Toxoplasma Infection

One of the stranger findings in Rh biology has come from research on Toxoplasma gondii, the common parasite carried by cats and found worldwide in human populations. Studies have reported that RhD status appears to modify how the body responds to Toxoplasma infection, with some effects of the infection being much stronger in RhD-negative individuals and others detectable only in certain RhD genotypes.²¹ The mechanisms behind this interaction remain unclear, and the research is still in relatively early stages. But it hints that the Rh system may have biological effects beyond what the current clinical framework accounts for, touching areas of physiology that have nothing to do with blood typing or pregnancy.